Skip to content

Online Videodensitometric Assessment of Aortic Regurgitation in the Cath-Lab

Online Videodensitometric Assessment of Aortic Regurgitation in the Cath-Lab

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04047082
Acronym
OVAL
Enrollment
100
Registered
2019-08-06
Start date
2019-05-15
Completion date
2019-09-30
Last updated
2019-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Insufficiency, Heart Valve Diseases, Paravalvular Aortic Regurgitation, Regurgitation, Aortic

Brief summary

Following the high feasibility of analyses by core laboratory with videodensitometry determined in the ASSESS-REGURGE Registry, this is an early clinical feasibility study of online videodensitometric assessment of aortograms to quantitate aortic regurgitation (AR) in the cath lab, specifically in the setting of transcatheter aortic valve replacement (TAVR)

Detailed description

OVAL (Online Videodensitometric Assessment of Aortic Regurgitation in the Cath-Lab) is a single centre, prospective, proof-of-principle, feasibility study performed in the Academic Medical Centre (Amsterdam). One hundred consecutive patients with aortic stenosis and indication to undergo TAVR by the Institution's Heart team are being enrolled in OVAL. All final aortograms will be performed according to predetermined acquisition protocol and analysed immediately after the acquisition in the cath-lab. All aortograms will also be analysed off-line by an independent core laboratory in the Netherlands (Cardialysis, Rotterdam, The Netherlands). The primary endpoint of the study is the feasibility of the on-line assessment of regurgitation (percentage of analysable cases). The secondary endpoint is the reproducibility of results between the on-line assessment and the off-line analysis by the independent core laboratory.

Interventions

DIAGNOSTIC_TESTQuantitative aortogram (videodensitometry)

Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)

Sponsors

Amsterdam University Medical Center
CollaboratorOTHER
Imperial College London
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Consecutive patients with indication to undergo TAVR by the Institution's Heart Team.

Exclusion criteria

* Patients that were not considered by the Institution's heart team as eligible

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of analysis(percentage of cases considered analyzable by videodensitometry - online)immediatelyFeasibility of analysis (percentage of cases considered analyzable by videodensitometry - online). The investigators will assess the percentage of cases that are considered by the investigators as analyzable (i.e., that the investigators are able to perform an on-line analysis of videodensitometry).
Comparison with feasibility of ASSESS-REGURGE ( to compare the percentage of analyzable cases with the percentage of the current standard found in ASSESS-REGURGE - 95.5%)immediatelySince ASSESS-REGURGE has the highest feasibility of analysis with quantitative aortogram, the investigators aim to compare the present feasibility (of OVAL) with the new standard from ASSESS-REGURGE. In other words, the percentage of analyzable cases in the present study will be compared with the percentage of analyzable cases found in ASSESS-REGURGE (95.5% of analyzability).

Secondary

MeasureTime frameDescription
Comparison of online feasibility with core lab feasibilityimmediatelyThe feasibility of analysis (i.e., if a cases is considered to be analyzable by videodensitometry) will be assessed on-line by the investigators and also assessed by an academic core laboratory. The result of the feasibility of analysis (percentage of analyzable cases) will be compared between the investigators assessment (on-line) and also by the core laboratory.

Countries

Netherlands

Contacts

Primary ContactPatrick W Serruys, MD, PhD
patrick.w.j.c.serruys@gmail.com+31102062828
Backup ContactYoshinobu Onuma, MD, PhD
yoshinobuonuma@gmail.com+31102062828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026